Honduras Pharmaceuticals and Healthcare Report Q2 2016

44 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Over the next ten years, there will be limited demand for advanced medicines within Honduras’
public healthcare system. Low-cost generic drugs will continue to dominate the local market. The
pharmaceutical market in Honduras will continue to be extremely unattractive to multinational drugmakers
due to the small market size, low growth rate and the fragmented, opaque and often-questionable public
procurement process.
Headline Expenditure Projections
Pharmaceuticals: HNL10.33bn (USDb473mn) in 2015 to HNL10.70bn (USD480mn) in 2016; +3.5% in
local currency terms, and +1.0% in US dollar terms. Our forecast has not changed since Q215.
Healthcare: HNL37.83bn (USDb1.73bn) in 2015 to HNL40.95bn (USD1.83n) in 2016; +8.3% in local
currency terms, and +5.6% in US dollar terms. Our forecast has been revised downwards since Q415 due to
revised macroeconomic data.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Honduras 2014-2020) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Honduras 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Honduras 2012-2020) 15
Industry Risk/Reward Index 16
Americas Risk/Reward Index 16
Industry Risk/Reward Index 22
Rewards 22
Risks 22
Regulatory Review 24
Market Overview 25
Healthcare Sector 25
Clinical Trials 29
Epidemiology 29
Competitive Landscape 32
Demographic Forecast 33
Demographic Outlook 33
Table: Population Headline Indicators (Honduras 1990-2025) 34
Table: Key Population Ratios (Honduras 1990-2025) 34
Table: Urban/Rural Population & Life Expectancy (Honduras 1990-2025) 35
Table: Population By Age Group (Honduras 1990-2025) 35
Table: Population By Age Group % (Honduras 1990-2025) 36
Glossary 38
Methodology 40
Pharmaceutical Expenditure Forecast Model 40
Healthcare Expenditure Forecast Model 40
Notes On Methodology 41
Risk/Reward Index Methodology 42
Index Overview 43
Table: Pharmaceutical Risk/Reward Index Indicators 43
Indicator Weightings 44

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Honduras 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Honduras 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Honduras 2012-2020)
Table: Population Headline Indicators (Honduras 1990-2025)
Table: Key Population Ratios (Honduras 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Honduras 1990-2025)
Table: Population By Age Group (Honduras 1990-2025)
Table: Population By Age Group % (Honduras 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Mexico Pharmaceuticals and Healthcare Report Q1 2015BMI View: The rising consumption of generic medicines will reshape Mexico's pharmaceutical industry. We expect the prevalence of generic drugs to increase rapidly over the forecast period - driven by government regulations supporting the sector and rising public awareness of off-patented medicines. Headline Expenditure Projections ? Pharmaceuticals: MXN172.74bn (USD13.53bn) in 2013 to MXN184.46bn (USD14.19bn) in 2014; +6.8% in local currency terms and +4.9% in US dollar terms. […]
  • Morocco Pharmaceuticals and Healthcare Report Q2 2015BMI View: A new wave of drug price cuts in Morocco and the implementation of the final stage of its universal healthcare coverage programme will see an improvement in the population's access to medicines. While increasing access to medicines is positive for drugmakers, we highlight that the Moroccan pharmaceutical market will become increasingly challenging for innovative drugmakers due to the lack of clarity regarding further medicine price cuts and the increasing market share of […]
  • Spain Pharmaceuticals and Healthcare Report Q1 2016BMI View: We maintain our subdued outlook for the Spanish pharmaceutical market. Price caps on originator medicines have negatively impacted the country's generic drug sector, which lags behind other European markets. However, new measures to improve access to generic and biosimilar medicines will lead to greater opportunities for generic drugmakers operating in the country. Headline Expenditure Projections ? Pharmaceuticals: EUR24.71bn (USD33.11bn) in 2014 to EUR25.18bn (USD27.70bn) […]
  • Switzerland Pharmaceuticals and Healthcare Report Q3 2015BMI View: The preference for patented drugs over low-value generic medicines by patients and prescribers in Switzerland will drive the government to continue to enforce measures that restrict growth in innovative medicine sales - particularly as the ageing population will boost the demand for long-term medicines. This will include price cuts on patented medicines as well as a push towards the greater promotion of lowervalue generic medicines. Headline Expenditure Projections ? […]